Consequences of SARS-CoV-2 pandemic on urological surgery in France: a nationwide analysis of the healthcare system database.
Adult oncology
COVID-19
UROLOGY
Journal
BMJ open
ISSN: 2044-6055
Titre abrégé: BMJ Open
Pays: England
ID NLM: 101552874
Informations de publication
Date de publication:
14 11 2022
14 11 2022
Historique:
entrez:
14
11
2022
pubmed:
15
11
2022
medline:
18
11
2022
Statut:
epublish
Résumé
The SARS-CoV-2 outbreak overwhelmed the healthcare systems worldwide. Saturation of hospitals and the risk of contagion led to a reduction in the care of other diseases. To determine the impact of SARS-CoV-2 pandemic on urological surgery in France during the year 2020. An observational descriptive study was conducted on anonymised data collected from the national healthcare database established each year as part of the Program for the Medicalization of Information Systems in Medicine, Surgery, Obstetrics and Odontology. None. We gathered the number of urology surgical procedures carried out between 2010 and 2019, and we observed the difference between the forecast and actual number of urological surgeries performed in 2020. Urological surgeries decreased by 11.4%, non-oncological surgeries being more affected (-13.1%) than oncological ones (-4.1%). Among the most relevant surgeries, female urinary incontinence (-44.7%) and benign prostatic hyperplasia (-20.8%) were the most impacted ones, followed by kidney cancer (-9%), urolithiasis (-8.7%), radical cystectomy for bladder cancer (-6.1%), prostate cancer (-3.6%) and transurethral resection of bladder tumour (-2%). Public hospitals had a more reduced activity (-17.7%) than private ones (-9.1%). Finally, the distribution of the reduction in urological activities by region did not correspond to the regional burden of SARS-CoV-2. Urological care was severely affected during SARS-CoV-2 pandemic. Even if oncological surgeries were prioritised, the longer it takes to receive appropriate care, the greater the risk on survival impact. The data collection and analysis was authorised by the French Data Protection Authority (CNIL) under the number1 861 282v2.
Identifiants
pubmed: 36375970
pii: bmjopen-2022-066220
doi: 10.1136/bmjopen-2022-066220
pmc: PMC9664026
doi:
Types de publication
Observational Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e066220Informations de copyright
© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: None declared.
Références
J Urol. 2021 Dec;206(6):1469-1479
pubmed: 34470508
J Clin Med. 2022 Jun 22;11(13):
pubmed: 35807210
PLoS One. 2022 Apr 21;17(4):e0267410
pubmed: 35446917
Annu Rev Control. 2020;50:373-393
pubmed: 33024411
Prog Urol. 2020 Apr;30(5):221-231
pubmed: 32224294
Swiss Med Wkly. 2020 Aug 11;150:w20331
pubmed: 32799308
Prog Urol. 2020 Jun - Jul;30(8-9):439-447
pubmed: 32430140
Surg J (N Y). 2021 Jun 03;7(2):e83-e91
pubmed: 34104720
Arch Intern Med. 2005 Mar 14;165(5):537-42
pubmed: 15767530
JCO Glob Oncol. 2021 Feb;7:311-323
pubmed: 33617304
Int Braz J Urol. 2020 Jul;46(suppl.1):170-180
pubmed: 32649082
Eur Urol. 2020 Jul;78(1):4-5
pubmed: 32349933
Prog Urol. 2020 Jun - Jul;30(8-9):414-425
pubmed: 32418734
Int J Clin Pract. 2021 Dec;75(12):e14965
pubmed: 34626151
Eur Urol. 2020 Jul;78(1):21-28
pubmed: 32376137
Best Pract Res Clin Anaesthesiol. 2021 Oct;35(3):351-368
pubmed: 34511224
Eur Urol Open Sci. 2020 Oct;21:22-28
pubmed: 33123688
Health Policy Technol. 2020 Dec;9(4):430-446
pubmed: 33520640
Future Oncol. 2021 Nov;17(32):4233-4235
pubmed: 34672692
Nat Rev Urol. 2020 Aug;17(8):425-427
pubmed: 32494029
Asian J Urol. 2017 Jul;4(3):148-151
pubmed: 29264223
World J Urol. 2022 Jan;40(1):277-282
pubmed: 34476595
Int J Environ Res Public Health. 2020 Nov 10;17(22):
pubmed: 33182696
Prog Urol. 2020 Jun - Jul;30(8-9):426-429
pubmed: 32389492
J Robot Surg. 2021 Dec;15(6):937-944
pubmed: 33511526